ClinicalTrials.gg
TerminatedNCT05358249KontRASt-03Updated Oct 21, 2026

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

A Phase 1/2 interventional study of JDQ443 and trametinib in KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung and Carcinoma, Non-Small-Cell Lung, sponsored by Novartis Pharmaceuticals. Terminated at 13 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

How we know · 11 judgments

Why this study was terminated
Business reasons and not based on any safety concerns.
Updated Oct 21, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis — 7 open to participants now, 15 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Novartis.

Enrollment
52nd of 92
74 · median 91
Started
2022
with 6 others
Phase 1/2
10 of 101
none open now
Registered
87th of 101
by date

Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 52nd largest by enrollment of the 92 interventional ones that give a count, is one of 7 that started in 2022, is one of 10 in phase 1/2, and was the 87th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, or all of them as a file.
02

Study summary

This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Read the detailed description

JDQ443 was considered "backbone" treatment in this trial and combined with selected therapies, or "partner(s)". The combination of a backbone and a partner constituted a treatment arm. After dose escalation, treatment arms that reached a maximum tolerated dose /recommended dose and were determined to be safe could, but were not required to, proceed to Phase II to further explore safety, tolerability, and anti-tumor activity.

03

Conditions studied

  • KRAS G12C Mutant Solid Tumors
  • Carcinoma, Non-Small Cell Lung
  • Carcinoma, Non-Small-Cell Lung
  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Carcinoma
  • Nonsmall Cell Lung Cancer
  • Colorectal Cancer
  • Colorectal Carcinoma
  • Colorectal Neoplasms
  • Colorectal Tumors
  • Neoplasms, Colorectal

Keywords

  • KRAS G12C
  • targeted therapy
  • NSCLC
  • CRC
  • advanced solid tumors
  • JDQ443
  • trametinib
  • ribociclib
  • cetuximab
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Dose Escalation:

- Patients with advanced ( or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.

Phase II:

  • Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and therapy, unless patient was ineligible to receive such therapy
  • Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy.

All patients:

  • performance status of 0 or 1.
  • Patients must have a site of disease amenable to and be a candidate for tumor biopsy according to the treating institution's guidelines.

Exclusion criteria

Exclusion Criteria:

  • Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
  • Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.
  • Active , including symptomatic brain metastases or known
  • cardiac disease or risk factors at screening
  • Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    JDQ443+trametinib

    JDQ443 in combination with trametinib

    Drug: JDQ443 · Drug: trametinib

  • Experimental
    JDQ443+ribociclib

    JDQ443 in combination with ribociclib

    Drug: JDQ443 · Drug: Ribociclib

  • Experimental
    JDQ443+cetuximab

    JDQ443 in combination with cetuximab

    Drug: JDQ443 · Biological: cetuximab

Interventions

  • DrugJDQ443

    KRAS G12C inhibitor, oral

  • MEK inhibitor, oral

    Also known as: TMT212

  • CDK4/6 inhibitor, oral

    Also known as: LEE011

  • Biologicalcetuximab

    EGFR inhibitor, intravenous

06

What researchers measure

Primary outcomes

  1. Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.

    A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value that is not primarily related to disease, disease progression, intercurrent illness/injury, or concomitant medications that occurs within the first 28 days of study treatment and meets a defined criteria.

    Time frame: 28 days

  2. Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment

    All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs).

    Time frame: 24 months

  3. Dose escalation: Frequency of dose interruptions and reductions, by treatment

    The number of patients with dose adjustments (reductions and interruptions) will be summarized by treatment group.

    Time frame: 24 months

  4. Dose Escalation: Dose intensity by treatment

    Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of response.

    Time frame: 24 months

  5. PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1

    ORR is the proportion of patients with a best overall response (BOR) of Complete Response (CR) or Partial Response (PR).

    Time frame: 24 months

Secondary outcomes

  1. Dose escalation and Phase II: ORR by local review per RECIST 1.1

    ORR is the proportion of patients with a BOR of CR or PR.

    Time frame: 24 months

  2. Dose escalation and Phase II: Disease Control Rate (DCR) by local review per RECIST 1.1

    DCR is the proportion of patients with a BOR of CR or PR or Stable Disease (SD). The objective of this endpoint is to summarize patients with signs of "activity" defined as either shrinkage of tumor (regardless of duration) or slowing down of tumor growth.

    Time frame: 24 months

  3. Dose escalation and Phase II: Duration of Response (DoR) by local review per RECIST 1.1

    Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause.

    Time frame: 24 months

  4. Dose escalation and Phase II: Progression-Free Survival (PFS) by local review per RECIST 1.1

    PFS is defined as the time from the date of start of treatment to the date of the first documented progression, or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

    Time frame: 24 months

  5. Phase II: DCR by BIRC per RECIST 1.1

    DCR is the proportion of patients with a BOR of CR or PR or SD. The objective of this endpoint is to summarize patients with signs of "activity" defined as either shrinkage of tumor (regardless of duration) or slowing down of tumor growth.

    Time frame: 24 months

  6. Phase II: DoR by BIRC per RECIST 1.1

    Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause.

    Time frame: 24 months

  7. Phase II: PFS by BIRC per RECIST 1.1

    PFS is defined as the time from the date of start of treatment to the date of the first documented progression, or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

    Time frame: 24 months

  8. Phase II: Overall survival (OS)

    OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.

    Time frame: 24 months

  9. Dose escalation and Phase II: PK parameters - Maximum Concentration (Cmax), as applicable per arm

    The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)

    Time frame: 5 months

  10. Dose escalation and Phase II: PK parameters - Minimum Concentration (Cmin), as applicable per arm

    Observed concentration at the end of a dosing interval (taken directly before next administration)

    Time frame: 5 months

  11. Dose escalation: Time to achieve Cmax - Tmax, as applicable per arm

    The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)

    Time frame: 5 months

  12. Dose escalation and Phase II: Plasma or serum concentration vs time profiles - AUCtau, as applicable per arm

    The Area under curve calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)

    Time frame: 5 months

  13. Dose escalation and Phase II: Plasma or serum concentration vs time profiles - AUCinf, as applicable per arm

    The AUC from time zero to infinity (mass x time x volume-1)

    Time frame: 5 months

  14. Phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment

    All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs).

    Time frame: 24 months

  15. Phase II: Frequency of dose interruptions and reductions, by treatment

    The number of patients with dose adjustments (reductions and interruptions) will be summarized by treatment group.

    Time frame: 24 months

  16. Phase II: Dose intensity by treatment

    Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of response.

    Time frame: 24 months

07

Study locations

13 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • NYU School of Medicine
    New York, New York 10015, United States
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Milan, MI 20162, Italy
  • Novartis Investigative Site
    Singapore, 168583, Singapore
  • Novartis Investigative Site
    Seoul, Seoul 03080, South Korea
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28050, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Sep 2026, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 3, 2022
StartActual
Oct 24, 2022
Primary completionActual
Sep 28, 2026
CompletionActual
Sep 28, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Business reasons and not based on any safety concerns.
changed Oct 21, 2026
Sites
1 site added, 1 site removed
Show site
  • Novartis Investigative Site · Seoul, South Korea
Show 1 removed
  • Novartis Investigative Site · Seoul, South Korea
Oct 21, 2026
Primary completion
Sep 30, 2026→Sep 28, 2026 (actual)
Oct 21, 2026
Study completion
Sep 30, 2026→Sep 28, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Terminated
    Why stopped Business reasons and not based on any safety concerns.
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · Seoul, South Korea
    Show 1 removed
    • Novartis Investigative Site · Seoul, South Korea
    Primary completion Sep 30, 2026→Sep 28, 2026 (now actual)
    Study completion Sep 30, 2026→Sep 28, 2026 (now actual)
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05358249
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Oct 24, 2022
Primary completion
Sep 28, 2026
Completion
Sep 28, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion